Literature DB >> 14589203

Biochemical injection treatment for discogenic low back pain: a pilot study.

Robert G Klein1, Björn C J Eek, Conor W O'Neill, Caren Elin, Vert Mooney, Richard R Derby.   

Abstract

BACKGROUND CONTEXT: Biochemical treatment options including attempts at intervertebral disc restoration are desirable for the physiologic treatment of degenerative disc disease.
PURPOSE: This was a pilot study to test the potential effectiveness of intradiscal injection therapy using agents known to induce proteoglycan synthesis in the treatment of intervertebral disc disease. STUDY
DESIGN: Prospective, within subject, experimental design was applied in the study. PATIENT SAMPLE: Thirty patients, average age 46.5 years, with chronic intractable low back pain of 8.5 years average duration, took part in the study. All patients had lumbar discography with reproduction of pain. OUTCOME MEASURES: Pretreatment Roland-Morris disability scores and visual analogue scores were compared with 1-year follow-up posttest values of these scores.
METHODS: Lumbar intervertebral discs were injected with a solution of glucosamine and chondroitin sulfate combined with hypertonic dextrose and dimethlysulfoxide (DMSO). Assessment of pain and disability was completed before treatment and an average of 12 months after the last treatment.
RESULTS: Posttreatment Roland-Morris scores for the entire group of 30 patients of 6.4+/-.994 were significantly (p<.001) lower than pretreatment scores of 12.0+/-.92 (mean+/-SE). The posttreatment visual analogue scores of 3.00+/-.44 were also significantly less than the pretreatment of 6.11+/-.33 (mean+/-SE). Although the results were statistically significant for the 30 patients as a whole, 17 of the 30 patients (57%) improved markedly with an average of 72% improvement in disability scores and 76% in visual analogue scores. The other 13 patients (43%) had little or no improvement. Patients who did poorly included those with failed spinal surgery, spinal stenosis and long-term disability. There were no complications or serious side effects, although postinjection pain was moderate to severe for 48 to 72 hours and required epidural steroids in five cases.
CONCLUSIONS: The results of this pilot study suggest that intradiscal injection therapy with glucosamine, chondroitin sulfate, hypertonic dextrose and DMSO warrants further evaluation with randomized controlled trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14589203     DOI: 10.1016/s1529-9430(02)00669-1

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  7 in total

Review 1.  Treatment of cervicothoracic pain and cervicogenic headaches with regenerative injection therapy.

Authors:  Felix S Linetsky; Rafael Miguel; Francisco Torres
Journal:  Curr Pain Headache Rep       Date:  2004-02

2.  Differences among outcome measures in occupational low back pain.

Authors:  Sue A Ferguson; William S Marras; Deborah L Burr
Journal:  J Occup Rehabil       Date:  2005-09

Review 3.  Prolotherapy: Potential for the Treatment of Chronic Wounds?

Authors:  Amir Hossein Siadat; Roslyn Rivkah Isseroff
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-04-03       Impact factor: 4.730

Review 4.  Biological treatment strategies for disc degeneration: potentials and shortcomings.

Authors:  Günther Paesold; Andreas G Nerlich; Norbert Boos
Journal:  Eur Spine J       Date:  2006-09-16       Impact factor: 3.134

Review 5.  Prolotherapy injections for chronic low-back pain.

Authors:  S Dagenais; M J Yelland; C Del Mar; M L Schoene
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

Review 6.  Bedside to bench and back to bedside: Translational implications of targeted intervertebral disc therapeutics.

Authors:  Gary Joel Rosenberg; Albert J M Yee; W Mark Erwin
Journal:  J Orthop Translat       Date:  2017-04-21       Impact factor: 5.191

7.  MicroRNA-221 silencing attenuates the degenerated phenotype of intervertebral disc cells.

Authors:  Letizia Penolazzi; Elisabetta Lambertini; Leticia Scussel Bergamin; Tosca Roncada; Pasquale De Bonis; Michele Cavallo; Roberta Piva
Journal:  Aging (Albany NY)       Date:  2018-08-20       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.